TSY-410

TSY-410 is a small molecule inhibitor of Ubiquitin-Specific Protease 1 (USP1), a deubiquitinating enzyme (DUB) that plays a critical role in DNA damage repair pathways, including the Fanconi Anemia (FA) pathway and Translesion Synthesis (TLS). Developed by Formosa Pharmaceuticals, TSY-410 is designed to exploit synthetic lethality in tumors with DNA repair deficiencies, such as those with BRCA1/2 mutations, and to sensitize cancer cells to conventional DNA-damaging therapies like platinum-based chemotherapy and PARP inhibitors. Beyond its oncology applications, TSY-410 is being investigated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), where USP1 inhibition is hypothesized to modulate fibrotic signaling and myofibroblast activation. The candidate is currently in Phase 1 clinical development for both solid tumors and IPF.